Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04756128Phase 2Completed

Impact of Colchicine and Low-dose Naltrexone on COVID-19

Role: collaborator

NCT00948311Completed

Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.

Role: collaborator

NCT00818142Completed

Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder

Role: collaborator

NCT00945711Completed

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

Role: collaborator

NCT00813280Completed

Barriers to the Implementation of Complete Insulin Order Sets

Role: collaborator

NCT01390636Terminated

Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

Role: collaborator

All 6 trials loaded